Initial efforts targeting prostate-specific membrane antigen (PSMA) provided essential proof-of-concept for TCEs in PCa [8] but also highlighted significant challenges regarding durability and toxicity. This evidence concerns the gene FOLH1 and posterior cortical atrophy.